SELLAS Life Sciences Group (SLS) Stock Price & Analysis

SLS$7.86-0.17 -2.12%
BiotechnologyGrowth Stock
Compare
Market cap$1.60BEnterprise value$1.45BRevenue (TTM)$0Market position—

Score

71
Bullish
Value
59
Quality
53
Growth
100

AI Analysis

Snapshot

SELLAS Life Sciences Group is a growth-led story right now — Growth 100/100 is the pillar doing the heavy lifting (overall 71/100) in Biotechnology. Under the hood: revenue compounding ~-100% annually over recent years. Street targets still imply ~345% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

59
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

100
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

53
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

SELLAS Life Sciences Group, Inc. (SLS) last printed $7.86. Equity value is $1.60B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$0.00$0.00$0.00$0.00$1.9M$7.6M$1M$0.00$0.00$0.00

About

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

SELLAS Life Sciences Group (SLS) Stock Price & Analysis

SLS price $7.86 -0.17 -2.12%

Ticker
SLS
Price
$7.86
Change
-0.17 -2.12%
Market cap
$1.60B
Dividend yield
0.00%
Beta
2.70
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
71
Value
59
Quality
53
Growth
100

Stocklytics score rationale: value 59, quality 53, growth 100.

Fair value

SLS fair value Not meaningful. Price $7.86.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price.

Fair value is the earnings value from next-twelve-months EPS times 28.4, a blend of the industry median and the stock's own 10-year median. A cash-flow value is not available for this stock. How we calculate it →

Not meaningful. The model is more than 80% below the live price, which happens for unprofitable or very early companies and is not a price target.

Compare SLS

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2027-03-25—-0.05—36.13M
2026-11-12-0.05-0.05——
2026-08-11-0.05-0.04——
2026-05-12-0.05-0.06——
2026-03-19-0.05-0.06——
2025-11-12-0.06-0.06——
2025-08-12-0.07-0.08——
2025-05-13-0.07-0.10——
2025-03-20-0.08-0.11——
2024-11-13-0.10-0.13——
2024-08-13-0.13-0.16——
2024-05-14-0.21-0.16——
2024-03-28-0.250.09—13.00M
2023-11-09-0.33-0.03—13.00M
2023-08-10-0.31-0.35—6.50M
2023-05-11-0.47-0.29——
2023-03-16-0.430.321.00M—
2022-11-14-0.34-0.39——
2022-08-11-0.41-0.35——
2022-05-12-1.05-0.381.00M1.00M
2022-03-31-0.42-0.407.60M—
2021-11-12-0.45-0.38——
2021-08-12-0.30-0.391.90M1.90M
2021-05-13-0.16-0.275.70M7.22M
2021-03-23-0.28—1.90M—
2020-11-13-0.53———
2020-08-13-0.66-0.64——
2020-05-14-0.66———
2020-03-13-1.54-0.72——
2019-11-14-2.68-1.00——
2019-08-14-6.50-9.00——
2019-05-15-10.50-13.50——
2019-03-22-23.50-15.50——
2018-11-15-26.50-20.50——
2018-08-15-63.00-54.00——
2018-05-15-73.50-46.50——
2018-04-132.28-53.00——
2017-11-09-30.00-225.00——
2017-08-14-330.00-270.00——
2017-05-10-675.00-330.00——

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-06-16Stergiou Angelos M.Buy1.06M——
2026-01-07Varian JohnBuy50.00K——
2026-01-07VAN NOSTRAND ROBERT LBuy50.00K——
2026-01-07SCHEINBERG DAVID ABuy50.00K——
2026-01-07CICIC DRAGANBuy300.00K——
2026-01-07Burns John ThomasBuy300.00K——
2026-01-07Kalin Katherine BachBuy50.00K——
2026-01-07Wasman JaneBuy50.00K——
2025-12-03CICIC DRAGANSell63.80K$1.5095.70K
2025-12-03Burns John ThomasSell58.59K$1.5087.89K
2025-12-03Stergiou Angelos M.Sell187.07K$1.50280.60K
2025-11-19Kalin Katherine BachBuy63.40K$1.59100.81K
2025-06-12VAN NOSTRAND ROBERT LBuy10.00K$1.4814.80K
2025-05-30Wasman JaneBuy20.00K$1.6933.80K
2025-05-22Kalin Katherine BachBuy20.00K$1.8036.00K
2025-01-10Burns John ThomasBuy81.30K——
2025-01-10Burns John ThomasBuy113.00K——
2025-01-10Burns John ThomasBuy169.50K$0.95161.45K
2025-01-10Stergiou Angelos M.Buy243.90K——
2025-01-10Stergiou Angelos M.Buy257.00K——
2025-01-10Stergiou Angelos M.Buy385.75K$0.95367.43K
2025-01-10SCHEINBERG DAVID ABuy12.50K——
2025-01-10SCHEINBERG DAVID ABuy18.50K$0.9517.62K
2025-01-10Wasman JaneBuy12.50K——
2025-01-10Wasman JaneBuy18.50K$0.9517.62K
2025-01-10VAN NOSTRAND ROBERT LBuy12.50K——
2025-01-10VAN NOSTRAND ROBERT LBuy18.50K$0.9517.62K
2025-01-10Kalin Katherine BachBuy12.50K——
2025-01-10Kalin Katherine BachBuy18.50K$0.9517.62K
2025-01-10Varian JohnBuy12.50K——
2025-01-10Varian JohnBuy18.50K$0.9517.62K
2025-01-10CICIC DRAGANBuy81.30K——
2025-01-10CICIC DRAGANBuy113.00K——
2025-01-10CICIC DRAGANBuy169.50K$0.95161.45K
2024-12-04CICIC DRAGANSell8.26K$1.139.33K
2024-12-04Stergiou Angelos M.Sell28.29K$1.1331.97K
2024-12-04Burns John ThomasSell7.17K$1.138.10K
2024-06-20CICIC DRAGANOther0——
2024-06-20CICIC DRAGANOther0$0.520
2024-06-20CICIC DRAGANOther0$3.340
2024-06-20CICIC DRAGANOther0$5.340
2024-06-20CICIC DRAGANOther0$8.000
2024-06-20CICIC DRAGANOther0$1.890
2024-01-22Stergiou Angelos M.Buy159.00K——
2024-01-22Stergiou Angelos M.Buy238.50K$0.52123.90K
2024-01-22SCHEINBERG DAVID ABuy6.00K——
2024-01-22SCHEINBERG DAVID ABuy10.00K$0.525.20K
2024-01-22WOOD BARBARA ABuy35.00K——
2024-01-22WOOD BARBARA ABuy50.00K$0.5225.97K
2024-01-22Kalin Katherine BachBuy10.00K$0.525.20K
2024-01-22Kalin Katherine BachBuy6.00K——
2024-01-22Wasman JaneBuy6.00K——
2024-01-22Wasman JaneBuy10.00K$0.525.20K
2024-01-22Francomano RobertBuy20.00K——
2024-01-22Francomano RobertBuy30.00K$0.5215.58K
2024-01-22Varian JohnBuy6.00K——
2024-01-22Varian JohnBuy10.00K$0.525.20K
2024-01-22VAN NOSTRAND ROBERT LBuy6.00K——
2024-01-22VAN NOSTRAND ROBERT LBuy10.00K$0.525.20K
2024-01-22Burns John ThomasBuy47.00K——
2024-01-22Burns John ThomasBuy75.00K$0.5238.96K
2023-12-06WOOD BARBARA ASell4.12K$1.084.45K
2023-12-06Stergiou Angelos M.Sell12.27K$1.0813.25K
2023-12-06Francomano RobertSell1.08K$1.081.17K
2023-12-06Burns John ThomasSell2.93K$1.083.16K
2023-02-02WOOD BARBARA ABuy80.00K$3.34267.20K
2023-02-02WOOD BARBARA ABuy20.00K——
2023-02-02Burns John ThomasBuy75.00K$3.34250.50K
2023-02-02Burns John ThomasBuy20.00K——
2023-02-02Stergiou Angelos M.Buy58.00K——
2023-02-02Stergiou Angelos M.Buy217.50K$3.34726.45K
2023-02-02Francomano RobertBuy45.00K$3.34150.30K
2023-02-02Francomano RobertBuy12.00K——
2023-02-02Varian JohnBuy9.50K$3.3431.73K
2023-02-02Varian JohnBuy2.50K——
2023-02-02Wasman JaneBuy9.50K$3.3431.73K
2023-02-02Wasman JaneBuy2.50K——
2023-02-02VAN NOSTRAND ROBERT LBuy9.50K$3.3431.73K
2023-02-02VAN NOSTRAND ROBERT LBuy2.50K——
2023-02-02SCHEINBERG DAVID ABuy9.50K$3.3431.73K
2023-02-02SCHEINBERG DAVID ABuy2.50K——
2023-02-02Kalin Katherine BachBuy9.50K$3.3431.73K
2023-02-02Kalin Katherine BachBuy2.50K——
2022-12-05Stergiou Angelos M.Sell6.49K$2.6116.94K
2022-12-05Burns John ThomasSell1.16K$2.593.00K
2022-12-05WOOD BARBARA ASell2.15K$2.595.58K
2022-08-13Kalin Katherine BachBuy19.00K——
2022-08-13Kalin Katherine BachBuy19.00K$3.1058.90K
2022-08-13Kalin Katherine BachOther0——
2022-03-14Francomano RobertBuy100.00K——
2022-03-14Francomano RobertOther0——
2022-01-31WOOD BARBARA ABuy13.00K——
2022-01-31WOOD BARBARA ABuy48.75K$5.34260.32K
2022-01-31Wasman JaneBuy7.12K$5.3438.05K
2022-01-31Wasman JaneBuy1.90K——
2022-01-31Varian JohnBuy7.12K$5.3438.05K
2022-01-31Varian JohnBuy1.90K——
2022-01-31VAN NOSTRAND ROBERT LBuy7.12K$5.3438.05K
2022-01-31VAN NOSTRAND ROBERT LBuy1.90K——
2022-01-31Stergiou Angelos M.Buy44.00K——

Institutional holders

Latest filed quarter: Q3 2026.

Institutions holding: 184, holders -51 vs prior quarter. Ownership 31.33%.

HolderSharesChangeChange %Value
BLACKROCK, INC.16.18M1.11M+7.37%199.20M
STATE STREET CORP10.37M-2.62M-20.19%127.69M
VANGUARD CAPITAL MANAGEMENT LLC8.94M716.54K+8.71%110.08M
ANSON FUNDS MANAGEMENT LP5.34M4.54M+567.59%65.74M
GEODE CAPITAL MANAGEMENT, LLC5.17M287.64K+5.89%63.68M
JANE STREET GROUP, LLC3.64M3.13M+615.20%44.76M
ANSON FUNDS MANAGEMENT LP3.10M2.30M+287.50%38.16M
VANGUARD PORTFOLIO MANAGEMENT LLC2.30M136.48K+6.32%28.28M
MORGAN STANLEY1.51M274.85K+22.23%18.60M
UBS GROUP AG1.49M232.52K+18.56%18.28M
VANGUARD FIDUCIARY TRUST CO1.44M106.11K+7.95%17.74M
DAGCO, INC.1.34M104.02K+8.44%16.45M
BARCLAYS PLC1.19M383.40K+47.83%14.59M
GROUP ONE TRADING LLC684.30K684.30KNew8.42M
BANK OF NEW YORK MELLON CORP521.13K-8.90K-1.68%6.42M
NUVEEN, LLC437.05K18.32K+4.38%5.38M
JANE STREET GROUP, LLC419.60K-88.83K-17.47%5.17M
OPUS CAPITAL GROUP, LLC403.63K18.03K+4.68%4.97M
SWISS NATIONAL BANK397.60K37.20K+10.32%4.89M
CREATIVE PLANNING368.73K368.73KNew4.54M
JPMORGAN CHASE & CO388.96K388.96KNew4.48M
MARSHALL WACE, LLP283.83K283.83KNew3.49M
LPL FINANCIAL LLC277.07K277.07KNew3.41M
ALPS ADVISORS INC267.55K267.55KNew3.29M
RAFFERTY ASSET MANAGEMENT, LLC245.95K6.05K+2.52%3.03M

Insights · Forecast · Financials · Learn

Stocklytics home · Screener